Recurrent oedema of the uvula in a patient with chronic spontaneous urticaria successfully treated with omalizumab

被引:1
|
作者
Pannofino, Alessandro [1 ]
机构
[1] Policoro Hosp, Operat Unit Med, Allergol & Immunol Clin, Via Salerno, I-75025 Policoro, Matera, Italy
关键词
Uvula oedema; chronic spontaneous urticaria; CSU; omalizumab; ANGIOEDEMA; DIAGNOSIS;
D O I
10.1080/09546634.2018.1550247
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Uvula oedema is a condition characterized by a sensation of a foreign body in the oropharynx and difficulty to speak; sometimes, if associated with glottis oedema, difficulty to breathe and dysphonia are also present. Urticaria is a disease characterized by itching wheals on the skin, and sometimes angioedema. Chronic urticaria is spontaneous when the etiology is unknown. Chronic urticaria may be disabling and difficult to treat, with a negative impact on the patient's quality of life. Omalizumab administration is suggested for refractory patients as add-on therapy to the antihistamines, in a third line. In Italy, omalizumab may be used for the treatment of spontaneous chronic urticaria in patients older than 12 years, refractory to antihistamines, with UAS >3 and UAS7 > 16. We describe a case of a 62-year-old woman had had recurring uvula oedema and chronic urticaria, not responder to antihistamines and oral corticosteroids. After 6 months of treatment with omalizumab and antihistamines, no urticaria recurrence was reported and no new episodes of angioedema had occurred. Our experience showed that omalizumab might be effective in patients with recurrent uvula oedema associated with urticaria.
引用
收藏
页码:8 / 9
页数:2
相关论文
共 50 条
  • [41] Profile of omalizumab in the treatment of chronic spontaneous urticaria
    Labrador-Horrillo, Moises
    Ferrer, Marta
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4909 - 4915
  • [42] How to discontinue omalizumab in chronic spontaneous urticaria?
    Turk, Murat
    Maurer, Marcus
    Yilmaz, Insu
    ALLERGY, 2019, 74 (04) : 821 - 824
  • [43] Bespoke omalizumab prescribing in chronic spontaneous urticaria
    Vandormael, Isabelle
    Font, Daniela Mock
    Carne, Emily
    Kamath, Sandeep
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I60 - I60
  • [44] How to discontinue omalizumab in chronic spontaneous urticaria?
    Turk, M.
    Maurer, M.
    Yilmaz, I
    ALLERGY, 2019, 74 : 610 - 611
  • [45] Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
    Maurer, Marcus
    Rosen, Karin
    Hsieh, Hsin-Ju
    Saini, Sarbjit
    Grattan, Clive
    Gimenez-Arnau, Ana
    Agarwal, Sunil
    Doyle, Ramona
    Canvin, Janice
    Kaplan, Allen
    Casale, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (10): : 924 - 935
  • [46] Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer
    Koremasa Hayama
    Hideki Fujita
    Mikiko Asai-Sato
    Kei Kawana
    Tadashi Terui
    European Journal of Dermatology, 2021, 31 : 100 - 101
  • [47] Chronic spontaneous urticaria or autoinflammatory disease? The therapeutic effect of omalizumab in a pediatric patient
    Maggio, Maria Cristina
    Lucania, Anna
    Collura, Mirella
    Corsello, Giovanni
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 : 14 - 16
  • [48] Chronic spontaneous urticaria and angioedema requiring treatment with omalizumab in a patient with hereditary angioedema
    Tadros, Susan
    Hayman, Grant R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 122 (06) : 666 - 667
  • [49] Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation?
    Tontini, Chiara
    Marinangeli, Lucia
    Cognigni, Miriam
    Bilo, Maria Beatrice
    Antonicelli, Leonardo
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (02) : 147 - 148
  • [50] Restoration of aspirin tolerance following omalizumab treatment in a patient with chronic spontaneous urticaria
    Asero, R.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 50 (05) : 226 - 228